Dashboard
1
High Management Efficiency with a high ROCE of 11.92%
2
Healthy long term growth as Net Sales has grown by an annual rate of 17.36% and Operating profit at 15.06%
3
Negative results in Jun 25
4
With ROCE of 4.18%, it has a very attractive valuation with a 1.26 Enterprise value to Capital Employed
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.22%
0%
14.22%
6 Months
49.81%
0%
49.81%
1 Year
23.62%
0%
23.62%
2 Years
20.87%
0%
20.87%
3 Years
-13.97%
0%
-13.97%
4 Years
27.17%
0%
27.17%
5 Years
193.09%
0%
193.09%
Shin Nippon Biomedical Laboratories, Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.36%
EBIT Growth (5y)
15.06%
EBIT to Interest (avg)
26.69
Debt to EBITDA (avg)
1.88
Net Debt to Equity (avg)
0.85
Sales to Capital Employed (avg)
0.46
Tax Ratio
19.10%
Dividend Payout Ratio
42.27%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.04%
ROE (avg)
24.18%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.40
EV to EBIT
30.12
EV to EBITDA
15.02
EV to Capital Employed
1.26
EV to Sales
2.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.18%
ROE (Latest)
12.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
6,477.70
5,549.50
16.73%
Operating Profit (PBDIT) excl Other Income
403.50
365.90
10.28%
Interest
57.80
40.60
42.36%
Exceptional Items
-6.20
-1.10
-463.64%
Consolidate Net Profit
256.50
114.40
124.21%
Operating Profit Margin (Excl OI)
-52.60%
-26.20%
-2.64%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 16.73% vs -4.40% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 124.21% vs -91.72% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
32,413.80
26,450.50
22.55%
Operating Profit (PBDIT) excl Other Income
5,596.30
6,030.30
-7.20%
Interest
202.70
138.80
46.04%
Exceptional Items
-230.90
8.30
-2,881.93%
Consolidate Net Profit
4,864.60
5,517.70
-11.84%
Operating Profit Margin (Excl OI)
92.10%
157.40%
-6.53%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 22.55% vs 5.42% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -11.84% vs -8.81% in Mar 2024
About Shin Nippon Biomedical Laboratories, Ltd. 
Shin Nippon Biomedical Laboratories, Ltd.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available






